News – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

Teitur Trophics CEO Simon Mølgaard Receives Rising Star Award at Biotech Spring Gala

2026.05.072026.05.07 / We are pleased to congratulate Simon Mølgaard, CEO of Teitur Trophics, on receiving the Rising Star Award at this year’s Biotech Spring Gala. The award, presented by DANISH BIO – Dansk Biotek, rec ...

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

2026.05.052026.05.05 / Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and ...

Theolytics

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

2026.04.282026.05.05 / OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1 ...

AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

2026.03.262026.03.26 / STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have ...

Boost Pharma

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

2026.03.192026.03.19 / Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imp ...

Hans Schambye - Boost Pharma

Developing possibly the first disease-modifying pediatric treatment for an agonizing condition

2026.03.162026.03.16 / BOOST Pharma aims to advance the development of a novel off-the-shelf cell therapy for children with an excruciating disease. And CEO Hans Schambye is leading the company onward to make it a reality. ...

AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s

2026.03.112026.03.11 / Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

Theolytics

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer

2026.03.052026.03.05 / Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer Competitive funding award highlights Theol ...

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

2026.02.252026.02.25 / Key highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for publication in Research and Practice in Thromb ...

Boost Pharma

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

2026.02.102026.02.10 / Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fract ...

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

2026.02.092026.02.09 / Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPD ...

Teitur Trophics Initiates Dosing of First Parkinson’s Disease Patient in Clinical Trial at CHDR, Leiden

2026.01.262026.01.26 / Teitur Trophics today announce the dosing of the first two patients with Parkinson’s disease in the Phase I trial for TT-P34, conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Net ...